All News
Day 2 Report from ACR21
This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.
Read Article
Axial spondyloarthritis with psoriasis or psoriatic spondylitis
PsA commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research question is whether PsSpA and Axial Spondyloarthritis (AxSpA) with psoriasis are separate conditions or not.
Read Article
This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24.
Reassuring data.
@RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx
sheila RHEUMarampa ( View Tweet)
Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC )
#ACR21
https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG
Links:
Dr. John Cush RheumNow ( View Tweet)
Interesting results where cannabidiol NEG results in RCT in hand OA and PsA. ? Throw out the ‘pot’with the dish water? Did it stimulate appetites? Was pain the same but interference less? Abst#1456 #ACR21 @RheumNow https://t.co/rnz82Paxkr
Janet Pope Janetbirdope ( View Tweet)
CBD for pain in hand OA/inactive PsA:
- works in animal models (many things do)
- other neg RCTs didn't use CBD itself
- DBRCT: 12w continuous, n=136, min dropout
Result:
does absolutely nothing
I bet big money it will be tried again & again
@Joner_MD #ACR21 ABST1456 @RheumNow https://t.co/lZLVrgrKST
David Liew drdavidliew ( View Tweet)
Among 6 CV risk algorithms, the best to predict the carotid plaque (CP) in PsA is the ACC/AHA risk score showed an AUC 0.681 (0.551-0.812), p=0.008, a cut-off point ≥4.8, sensitivity of 63.6%, and specificity of 64.4%
⭐️Prevalence CP 42.3%
Abst #1315 #ACR21 @RheumNow https://t.co/hRvyjetYq3
swethaann23 swethaann23 ( View Tweet)
Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia
⭐️Anemia resolution associated with improved clinical status
#ACR21
#ACRBest
Abs#1331
@RheumNow
https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed
Robert B Chao, MD doctorRBC ( View Tweet)
Knowledge Bowl at #ACR21
⭐️This HLA allele confers a risk for a severe psoriasis phenotype, typically guttate type.
➡️HLA Cw6
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abst1344 #ACR21 @RheumNow observational study of pts w/PsA treated w/b&tsDMARD:pts who achieve MDA (22.8% of pts at 6 mo) more likely to maintain the initiated bDMARD or tsDMARD Rx & less likely to switch from the initiated bDMARD/tsDMARD https://t.co/egFDHV3eQs
Olga Petryna DrPetryna ( View Tweet)
AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0
Dr. Antoni Chan synovialjoints ( View Tweet)
SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX
Dr. Rachel Tate uptoTate ( View Tweet)
Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and without background csDMARD use.
⭐️>60% w/ background csDMARD use, majority of which was MTX
⭐️no difference in AE
#ACR21
Abs#1352
@RheumNow
https://t.co/nIJT7rNkJP https://t.co/bq0x1Ywguo
Robert B Chao, MD doctorRBC ( View Tweet)
Younger age, male gender, geographic region, lower weight and BMI, dactylitis+ or enthesitis+, lower scores Pt-Pain, PtGA, TJC and HAQ-DI were baseline predictors for achieving MDA and DAPSA LDA at Week 56 in UPA treated patients @RheumNow #ACR21 Abst#1348 https://t.co/FSXarBoBM1 https://t.co/UMCjr6eCRm
Dr. Antoni Chan synovialjoints ( View Tweet)
Physical exercise did not increase BME disease in SIJ and spine in PsA. The risk of increased BME after 11 weeks of HIIT was not higher compared to controls in a cohort of PsA patients with low to moderate disease activity @RheumNow #ACR21 Abst#1362 https://t.co/DHj4D5Ojb1 https://t.co/J4KV5zdpey
Dr. Antoni Chan synovialjoints ( View Tweet)
Abst1424 #ACR2021 @RheumNow study of SEC in children w/ERA or JPsA : 72% reduced flare risk. Improved JADAS-27 score in both the ERA and JPsA categories. ⬇️ disease activity, enthesitis count & joints with active arthritis. adverse events & serious AEs in the SEC & PBO comparable https://t.co/J4MdxeYxWZ
Olga Petryna DrPetryna ( View Tweet)
PsO pts not on biologics had a ⬆️ risk of PsA compared to those on biologics
⭐️HR 1.39
⭐️retrospective cohort study w/ >1300 cases
Abs#1355
#ACR21
#ACRBest
@RheumNow
https://t.co/tL37we3lwc https://t.co/SAexvn9HMb
Robert B Chao, MD doctorRBC ( View Tweet)
In PsA patients with low baseline CRP treated with IXE or ADA, a favorable reduction in pain was observed for IXE-treated
patients, irrespective of controlled or non-controlled inflammation, as
measured by CRP or SJC improvement @RheumNow #ACR21 Abst#1341 https://t.co/Nl78oASmf5 https://t.co/2qSXQr2sQS
Dr. Antoni Chan synovialjoints ( View Tweet)
Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
Richard Conway RichardPAConway ( View Tweet)
Study on enthesitis response to biologic Rx
⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab
⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab
🔰Superiority of TNFi versus secukinumab in regards to active enthesitis
Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ
swethaann23 swethaann23 ( View Tweet)
